Semler Scientific to Report First Quarter Financial Results and Host Conference Call on May 7, 2024
Semler Scientific to Report First Quarter Financial Results and Host Conference Call on May 7, 2024
SANTA CLARA, Calif., April 23, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a company that develops, manufactures and markets innovative medical products and services that assist in evaluating and treating chronic diseases, today announced that it will report financial results for the first quarter ended March 31, 2024, after the close of U.S. financial markets on Tuesday, May 7, 2024. Doug Murphy-Chutorian, M.D., chief executive officer of Semler Scientific, will host a conference call at 4:30 pm ET the same day. Renae Cormier, chief financial officer, and Jennifer Oliva-Herrington, chief operating officer, will join him on the call.
加利福尼亞州聖克拉拉，2024年4月23日 /PRNewswire/ — 開發、製造和銷售有助於評估和治療慢性病的創新醫療產品和服務的公司塞姆勒科學公司（納斯達克股票代碼：SMLR）今天宣佈，將在2024年5月7日星期二美國金融市場收盤後公佈截至2024年3月31日的第一季度財務業績。塞姆勒科學首席執行官道格·墨菲-丘托里安醫學博士將於美國東部時間當天下午 4:30 主持電話會議。首席財務官雷娜·科米爾和首席運營官詹妮弗·奧利瓦-赫靈頓將與他一起參加電話會議。
We encourage participants to pre-register for the conference call using the following link: . Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
我們鼓勵參與者使用以下鏈接預註冊電話會議：。 預註冊的呼叫者將獲得會議密碼和唯一的PIN，以便立即訪問通話並繞過現場接線員。參與者可以隨時進行預註冊，包括在通話開始之前和之後。
Those without internet access or unable to pre-register may dial in by calling:
Domestic callers: 833-816-1161
International callers: 412-317-0717
那些無法上網或無法預註冊的人可以通過撥打以下電話進行撥號：
國內來電者：833-816-1161
國際來電者：412-317-0717
Please specify to the operator that you would like to join the "Semler Scientific Call." The conference call will be archived on Semler Scientific's website at .
請向操作員說明您想參加 “Semler 科學電話會議”。電話會議將存檔在 Semler Scientific 的網站上，網址爲。
About Semler Scientific, Inc.:
Semler Scientific, Inc. develops, manufactures and markets innovative products and services that assist in evaluating and treating chronic diseases. Its flagship product, QuantaFlo, which is patented and cleared by the U.S. Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and Semler Scientific is seeking a new 510(k) clearance for expanded indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). Semler Scientific has a minority investment in Mellitus, SYNAPS Dx, as well as Monarch Medical Technologies LLC, a privately held company whose product EndoTool offers a technological solution for inpatient glycemic management. Additional information about Semler Scientific can be found at .
關於塞姆勒科學公司：
Semler Scientific, Inc. 開發、製造和銷售有助於評估和治療慢性病的創新產品和服務。其旗艦產品QuantaFlo已獲得美國食品藥品監督管理局（FDA）的專利和批准，是一種測量四肢動脈血流的快速即時檢測。QuantaFlo測試有助於診斷心血管疾病，例如外周動脈疾病（PAD），塞姆勒科學正在尋求新的510（k）許可證，以擴大適應症。醫療保健提供者使用QuantaFlo來評估患者的死亡風險和重大心血管不良事件（MACE）。塞姆勒科學對Mellitus、SYNAPS Dx以及Monarch Medical Technologies LLC進行了少數股權投資，後者是一傢俬營公司，其產品EndoTool爲住院患者血糖管理提供技術解決方案。有關 Semler Scientific 的更多信息，請訪問。
CONTACT:
聯繫人：
Renae Cormier, CFO
[email protected]
首席財務官 Renae Cormier
[電子郵件保護]
SOURCE Semler Scientific, Inc.
來源 Semler Scientific, Inc.
譯文內容由第三人軟體翻譯。